Simulations Plus, Inc. - SLP STOCK NEWS

Simulations Plus (Nasdaq: SLP) has launched version 9.8.1 of its GastroPlus® software, enhancing its pharmacokinetics modeling capabilities. Key upgrades include improved drug-drug interaction (DDI) models, new options for lung deposition variability, and better data import processes. These advancements aim to streamline regulatory reviews and enhance communication between health authorities and drug sponsors. The updates are expected to expedite the marketing of new drug products, reinforcing GastroPlus as a leading PBPK software platform.

Simulations Plus (Nasdaq: SLP) announced a distribution agreement with Mosim, a premier biopharmaceutical services company in China, to distribute the MonolixSuite™ PK/PD modeling platform. This partnership aims to enhance the understanding and application of pharmacokinetics and pharmacodynamics in China’s pharmaceutical sector, which is experiencing rapid growth. Mosim's extensive industry connections will support the promotion of MonolixSuite, which includes tools such as PKanalix, Monolix, and Simulx. This agreement strengthens Simulations Plus' market presence in the burgeoning Chinese pharmaceutical market.

Simulations Plus, Inc. (Nasdaq: SLP) has entered a distribution agreement with the Institute of Pharmaceutical Sciences (ICF) to enhance marketing and sales support in South America. ICF, a leading pharmaceutical research center, will leverage its expertise and connections to promote Simulations Plus’s products, including GastroPlus® and ADMET Predictor®. This partnership aims to capitalize on the growing $48 billion Latin American generic drug market by advancing model-informed drug development (MIDD) strategies, providing opportunities for research and regulatory interactions.

Simulations Plus, a leader in the pharmaceutical software industry, reported a successful partnership with Makerere University, enhancing its global reach in pharmacokinetic services. This initiative aims to optimize drug development through advanced modeling solutions. The collaboration is expected to significantly bolster the company's influence in academic research.

Furthermore, Simulations Plus continues to expand its client base, attracting more pharmaceutical firms looking to improve their drug pipelines. The stock remains robust, with positive projections for future growth.

Simulations Plus, Inc. (Nasdaq: SLP) announced that CEO Shawn O’Connor will present at the 23rd Annual Needham Virtual Growth Conference on January 14, 2021, at 2:00 p.m. ET. O’Connor will also conduct one-on-one meetings throughout the day. The conference will showcase presentations from nearly 500 leading public and private companies, providing a platform for investors and shareholders. For more details or to arrange a meeting with O’Connor, contact Hayden IR at slp@haydenir.com.

Simulations Plus, Inc. (Nasdaq: SLP) has entered a new funded collaboration with a major pharmaceutical company to enhance machine learning models and physiologically based pharmacokinetics/pharmacodynamics (PBPK/PD) approaches for treating pulmonary infections. Significant investments from the partner are set to make Simulations Plus' technology a key component of their research strategy. The collaboration will utilize the ADMET Predictor® and GastroPlus® platforms to inform drug discovery and development, focusing on specific populations for greater regulatory acceptance.

Simulations Plus, Inc. (Nasdaq: SLP) reported a 14% revenue increase to $10.7 million for Q1 FY2021, with gross profit rising 22% to $8.3 million. Gross margin improved to 77% from 72%, and net income increased 21% to $2.5 million. Diluted earnings per share reached $0.12, up 9%. CEO Shawn O’Connor noted strong double-digit growth despite tough comparisons to FY2020. Key factors include strategic investments and the Lixoft acquisition, which expanded market reach. The company forecasts an organic growth of 15% to 20% for the fiscal year, alongside a declared dividend of $0.06 per share.

Simulations Plus (Nasdaq: SLP) has announced a new collaboration with a major pharmaceutical company to enhance its GastroPlus® Advanced Compartmental Absorption and Transit (ACAT™) model for oral peptide formulations. The project aims to improve intestinal absorption simulations for larger molecules, utilizing unique data from the partner. This partnership aligns with the growing demand for oral therapeutic peptides, expanding the company's modeling capabilities. All enhancements will be available to SLP’s user community, aiming to accelerate drug development timelines.

Simulations Plus, Inc. (Nasdaq: SLP) will report its financial results for the first quarter of fiscal year 2021 after the market closes on January 11, 2021. A conference call will follow at 4:15 p.m. Eastern Time, inviting all interested parties to join by registering online or via phone. The call will also be available as a live webcast. Simulations Plus specializes in modeling and simulation software for drug discovery and development, with its technology used by several major pharmaceutical and biotechnology companies worldwide.